Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CATALYST PHARMACEUTICALS, INC. Director's Dealing 2025

Nov 25, 2025

31542_dirs_2025-11-24_954a4fd1-5734-4469-a864-1d0a8e1782cc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2025-11-20

Reporting Person: Sundaram Preethi (Chief Strategy Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-11-21 Common Stock, par value $0.001 per share M 5603 Acquired 46684 Direct
2025-11-21 Common Stock, par value $0.001 per share F 1364 Disposed 45320 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-11-20 Options to purchase common stock $22.77 A 106873 Acquired 2032-11-20 Common Stock (106873) Direct
2025-11-20 Restricted Stock Units $ A 32257 Acquired Common Stock (32257) Direct
2025-11-21 Restricted Stock Units $ M 5603 Disposed Common Stock (5603) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

F2: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.

F3: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.

F4: Shares of common stock will be delivered to the Reporting Person upon vesting.

F5: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.

F6: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.